Search academic texts

Information × Registration Number 0222U002251, 0119U002051 , R & D reports Title Identifying factors for long-term survival in patients with multiple myeloma in conditions of modern therapy and developing management strategy for these patients after achieving treatment response. popup.stage_title Head Masliak Zvenyslava V, Registration Date 11-02-2022 Organization State institution "Institute of blood pathology and transfusion medicine of Nataional Academy of Medical scinces of Ukraine" popup.description2 The study comprises 100 patients (pts) with multiple myeloma (46 males and 54 females), 82% were younger than 65. Treatment included thalidomide, bortezomib based schemes as well as new combination of bortezomib with lenalidomide (VRD). Patients ≤ 65 who achieved at least PR underwent HDCT followed by auto-HSCT. It was found that survival of the patients taking standard treatment was not dependent on their age, type of light and heavy chains however overall survival was significantly higher in males. The best response was achieved by patients treated with VRD – overall response rate - 99%. This parameter was lower (86,8%) in patients treated with bortezomib and other drugs. Overall response rate after thalidomide-containing schemes was 80%. In 30 pts auto-HSCT was performed in the institute. Two types of mobilization regimens were applied based on cyclophosphamide or etoposide with methylprednisolone. Evaluation of immunophenotype was performed in 50 pts with MM prior to treatment as well as in 49 pts after treatment for CR confirmation. All bone marrow plasma cells had signs of malignant myeloma with high density expression of CD38 and CD138 antigens, lack CD19 or CD20. Myeloma cells (CD38+/CD138+) were further investigated for expression of other antigens. Reduction of T-cells and subpopulations after CR was noted. Evaluation of cytogenetic abnormalities in bone marrow plasma cells of 46 pts with MM was performed. Frequency of adverse chromosomal aberrations by FISH accounted for 45,6%. Shorter OS was found in patients with cytogenetic abnormalities as compared to normal karyotype. Introduction of auto-HSCT was able to overcome the adverse prognosis related to presence of cytogenetic abnormalities of high risk. Clinical disease course was described for 5 pts with new cytogenetic aberration – amplification of the long arm of chromosome 1, which had an adverse prognostic impact. Product Description popup.authors Vygovska Yaroslava I Horodys'ka Tetyana O Dorosh Lilia V Knysh Nataliya V Lukavets'kyj Les' M Maslyak Zvenyslava V Melnyk Mariya I Prymak Sofiya V Prystavska Khrystyna B Thir Hrystyna R Tsyapka Orest M popup.nrat_date 2022-03-09 Close